1. Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma
    Elena V. Poddubskaya et al, 2018, Exp Hematol Oncol CrossRef
  2. The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium
    Alessandra Gentilini et al, 2018, IJMS CrossRef
  3. Combined hepatocellular-cholangiocarcinoma successfully treated with sorafenib: case report and review of the literature
    Yuka Futsukaichi et al, 2018, Clin J Gastroenterol CrossRef
  4. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma
    Weijing Sun et al, 2018, Cancer CrossRef
  5. Causes of hOCT1‐Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor‐Selective Gene Therapy
    Elisa Lozano et al, 2019, Hepatology CrossRef
  6. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial.
    A Demols et al, 2020, Ann Oncol CrossRef
  7. The interaction of LOXL2 with GATA6 induces VEGFA expression and angiogenesis in cholangiocarcinoma.
    Tao Peng et al, 2019, Int J Oncol CrossRef

  8. Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma


    Guohe Lin et al, 2020, CMAR CrossRef
  9. Regorafenib, an investigational agent for the treatment of cholangiocarcinoma
    Ibrahim Halil Sahin et al, 2020, Expert Opinion on Investigational Drugs CrossRef
  10. Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance
    Jose J. G. Marin et al, 2021, Cancers CrossRef
  11. The Tumor Environment: Cholangiocarcinoma-Associated Fibroblasts and Beyond
    Anja Moncsek et al, 2021 CrossRef
  12. Autophagy activity in cholangiocarcinoma is associated with anatomical localization of the tumor
    Gábor Lendvai et al, 2021, PLoS ONE CrossRef
  13. Patient-Derived Organoids of Cholangiocarcinoma
    Christopher Fabian Maier et al, 2021, IJMS CrossRef
  14. Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine
    Riccardo Carloni et al, 2022, Translational Oncology CrossRef
  15. Label-Free Imaging Analysis of Patient-Derived Cholangiocarcinoma Organoids after Sorafenib Treatment
    Michael Koch et al, 2022, Cells CrossRef
  16. The role of metabolic reprogramming in liver cancer and its clinical perspectives
    Mengxiao Lu et al, 2024, Front. Oncol. CrossRef